Significados de cytokine release syndrome en inglés

Grade 3 cytokine release syndrome occurred in one patient.

Administration is associated with mild to moderate (but transient) cytokine release syndrome, readily managed in the outpatient setting.

The most common is cytokine release syndrome, where the body appears to react to the mass killing of tumor cells.

Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation.

Also, seven of the patients developed cytokine release syndrome so severe that they required intensive care, and a further two patients died.

About half the patients experienced a serious complication known as cytokine release syndrome (CRS) which occurs when the body's immune system goes into overdrive.

More than half of patients experienced a serious complication known as cytokine release syndrome (CRS) which occurs when the body's immune system goes into overdrive.

Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness.

The proposed mechanisms for many cytokine -directed and anti-rejection drugs are focused on evidence of efficacy in cytokine release syndromes in humans or animal models.

Two patients experienced Grade II or III cytokine release syndromes and developed controllable Grade II intestinal acute graft-versus-host disease (GVHD) or limited chronic oral GVHD.